Home > > > > Report Detail

US Biosimilar Market: Insights & Forecast with Potential Impact of COVID- 19 (2022-2026)

Publisher Name :
Date: 01-Jul-2022
No. of pages: 108
Inquire Before Buying

The US biosimilar market is forecasted to reach US$36.16 billion in 2026, experiencing growth at a CAGR of 40.16% during the period spanning from 2022 to 2026. Growth in the US biosimilar market is supported by factors such as rising prevalence of cancer, growing geriatric population and favorable environment. However, the market growth is expected to be restrained by complexities in manufacturing, excess competition and complexities in pricing.

The US biosimilar market by drug class can be segmented as follows: monoclonal antibodies, filgrastim & pegfilgrastim and others. In 2021, the dominant share of the US biosimilar market was being held by monoclonal antibodies, followed by filgrastim & pegfilgrastim. As of 2021, there are around 90 biosimilar products in the pipeline and 33 approved biosimilar products in the US.

The US biosimilar market by product can be categorized as follows: Prolia (Denosumab), Xolair (Omalizumab), Rituxan (Rituximab), Humira (Adalimumab) and Stelara (Ustekinumab). The US Biosimilar market landscape by class can be categorized as follows: Supportive Care, Oncology, Long Acting Insulin, Rapid Acting Insulin, Ophthalmology and TNF blockers. Factors such as patent expiry Of biologics and research on new indications has been supporting the US biosimilar market.

The COVID-19 pandemic has introduced new challenges for the pharmaceutical industry, including makers of biosimilars. The pandemic threatened to derailed product pipelines. During the height of the outbreak, resources were diverted away from the research and development of new biosimilars and towards the fight against Covid-19.

Scope of the report:


  • The report provides a comprehensive analysis of the US biosimilar market with impact of COVID-19.

  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

  • The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Novartis AG, Amgen Inc., Samsung Biologics Co., Ltd., Celltrion, Inc. and Viatris Inc.) are also presented in detail.


Key Target Audience:


  • Biosimilar Companies

  • Biologics Companies

  • Hospitals

  • Consumers

  • Pharmaceutical companies

  • Investment Banks

  • Government Bodies & Regulating Authorities

US Biosimilar Market: Insights & Forecast with Potential Impact of COVID- 19 (2022-2026)

Table of Contents

1. Market Overview
1.1 Biosimilar
1.1.1 Biosimilar- Introduction
1.1.2 Need for Biosimilars
1.2 Difference between Biologic, Biosimilar and Generic Drugs
1.3 FDA-Approved Biosimilar Products
1.4 Applications of Biosimilar
1.5 Advantages of Biosimilar
1.6 Disadvantages of Biosimilar
1.7 Biosimilar Development

2. Impact of COVID- 19
2.1 Impact of COVID-19 on the US Biosimilar Market
2.2 Delayed Approvals
2.3 Inaccessibility Of Healthcare Providers (HCPs)
2.4 Postponement of Inspection
2.5 Decrease in Prices
2.6 Post-COVID Scenario

3. The US Market Analysis
3.1 The US Biosimilar Market Forecast by Value
3.2 The US Biosimilar Market by Drug Class
3.3 The US Biosimilar Approvals
3.4 The US Biosimilar Launches
3.5 The US Biosimilar in Pipeline
3.6 The US Biosimilar Market by Product
3.6.1 The US Prolia (Denosumab) Biosimilar Market Forecast by Value
3.6.2 The US Xolair (Omalizumab) Biosimilar Market Forecast by Value
3.6.3 The US Rituxan (Rituximab) Biosimilar Market Forecast by Value
3.6.4 The US Humira (Adalimumab) Biosimilar Market Forecast by Value
3.6.5 The US Stelara (Ustekinumab) Biosimilar Market Forecast by Value
3.7 The US Biosimilar Market Landscape
3.7.1 The US Supportive Care Biosimilar Market Landscape
3.7.2 The US Oncology Biosimilar Market Landscape
3.7.3 The US Long Acting Insulin Biosimilar Market Landscape
3.7.4 The US Rapid Acting Insulin Biosimilar Market Landscape
3.7.5 The US Ophthalmology Biosimilar Market Landscape
3.7.6 The US TNF blockers Biosimilar Market Landscape
3.8 The US Biosimilar Pipeline Landscape
3.8.1 The US Supportive Care Biosimilar Pipeline Landscape
3.8.2 The US Oncology Biosimilar Pipeline Landscape
3.8.3 The US Insulin Biosimilar Pipeline Landscape
3.8.4 The US Ophthalmology Biosimilar Pipeline Landscape
3.8.5 The US TNF blockers Biosimilar Pipeline Landscape
3.8.6 The US Immunosuppressant Biosimilar Pipeline Landscape
3.8.7 The US Bone Health Biosimilar Pipeline Landscape
3.8.8 The US Growth Hormone Biosimilar Pipeline Landscape
3.8.9 The US Infertility Biosimilar Pipeline Landscape

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Prevalence of Cancer
4.1.2 Increasing Health Expenditure
4.1.3 Growing Geriatric Population
4.1.4 Payors Favoring Biosimilars
4.1.5 Cost Effective
4.1.6 Favorable Environment
4.2 Key Trends & Developments
4.2.1 Patent Expiry of Biologics
4.2.2 Research on New Indications
4.3 Challenges
4.3.1 Complexities in Manufacturing
4.3.2 Excess Competition
4.3.3 Complexities in Pricing

5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison- Key Players
5.1.2 Market Capitalization Comparison- Key Players
5.1.3 FDA Approved Biosimilars- Key Players
5.1.4 Forecasted Market Share - Key Players
5.1.5 Biosimilar Cancellation Cases- Key Players
5.1.6 Avastin (Bevacizumab) Biosimilar Developers
5.1.7 Prolia (Denosumab) Biosimilar Developers
5.1.8 Rituxan (Rituximab) Biosimilar Developers
5.1.9 Stelara (Ustekinumab) Biosimilar Developers
5.1.10 Humira (Adalimumab) Biosimilar Developers
5.1.11 Xolair (Omalizumab) Biosimilar Developers

6. Company Profiles
6.1 Celltrion, Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Samsung Biologics Co., Ltd.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Pfizer Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.5 Novartis AG
6.5.1 Business Overview
6.5.2 Financial Overview
6.5.3 Business Strategies
6.6 Viatris Inc.
6.6.1 Business Overview
6.6.2 Financial Overview
6.6.3 Business Strategies

List of Figures

Applications of Biosimilar
Advantages of Biosimilar
Disadvantages of Biosimilar
Biosimilar Development
The US Biosimilar Market Forecast by Value (2021-2026)
The US Biosimilar Market by Drug Class (2021)
The US Biosimilar Approvals (2015-2021)
The US Biosimilar Launches (2015-2021)
The US Biosimilar in Pipeline (As of 2021)
The US Prolia (Denosumab) Biosimilar Market Forecast by Value (2018-2025)
The US Xolair (Omalizumab) Biosimilar Market Forecast by Value (2018-2025)
The US Rituxan (Rituximab) Biosimilar Market Forecast by Value (2018-2025)
The US Humira (Adalimumab) Biosimilar Market Forecast by Value (2018-2025)
The US Stelara (Ustekinumab) Biosimilar Market Forecast by Value (2023-2025)
The US Supportive Care Biosimilar Market Landscape
The US Oncology Biosimilar Market Landscape
The US Long Acting Insulin Biosimilar Market Landscape
The US Rapid Acting Insulin Biosimilar Market Landscape
The US Ophthalmology Biosimilar Market Landscape
The US TNF blockers Biosimilar Market Landscape
The US Supportive Care Biosimilar Pipeline Landscape
The US Oncology Biosimilar Pipeline Landscape
The US Insulin Biosimilar Pipeline Landscape
The US Ophthalmology Biosimilar Pipeline Landscape
The US TNF blockers Biosimilar Pipeline Landscape
The US Immunosuppressant Biosimilar Pipeline Landscape
The US Bone Health Biosimilar Pipeline Landscape
The US Growth Hormone Biosimilar Pipeline Landscape
The US Infertility Biosimilar Pipeline Landscape
The US Estimated New Cancer Cases in (2017-2021)
The US National Health Expenditure (2015-2020)
The US population 65 Years & Older (2020-2060)
Share of Health Plans Preferring Biosimilars Over Reference Product (2020)
North America Unique Parenteral Biologic Molecule LoP Events (2021-2030)
Key Players – Forecasted Market Share (2021- 2025)
Products
Celltrion, Inc. Sales and Net Profit (2017-2021)
Samsung Biologics Co., Ltd. Revenue and Profit (Loss) (2017-2021)
Samsung Biologics Co., Ltd. Revenue By Region (2021)
Amgen Inc. Total Revenues and Net Income (2017-2021)
Amgen Inc. Total Revenues By Region (2021)
Segments
Pfizer Inc. Revenues and Net Income (2017-2021)
Pfizer Inc. Revenues By Segment (2021)
Pfizer Inc. Revenues By Region (2021)
Segments
Novartis AG Net Sales and Net Income (2017-2021)
Novartis AG Net Sales by Segment (2021)
Novartis AG Net Sales by Region (2021)
Viatris Inc. Net Sales and Net (Loss) Earnings (2018-2021)
Viatris Inc. Net Sales by Segment (2021)

List of Tables

Difference between Biologics, Biosimilar and Generic Drugs
FDA-Approved Biosimilar Products
FDA-Approved Biosimilar Products (2020)
Key Players - Revenue Comparison (2021)
Key Players – Market Capitalization Comparison (2022)
FDA Approved Biosimilars- Key Players
Key Players – Biosimilar Cancellation Cases
Avastin (Bevacizumab) Biosimilar Developers
Prolia (Denosumab) Biosimilar Developers
Rituxan (Rituximab) Biosimilar Developers
Stelara (Ustekinumab) Biosimilar Developers
Humira (Adalimumab) Biosimilar Developers
Xolair (Omalizumab) Biosimilar Developers

  • Global Biologics and Biosimilars Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 147
    According to our LPI (LP Information) latest study, the global Biologics and Biosimilars market size was valued at US$ 458090 million in 2023. With growing demand in downstream market, the Biologics and Biosimilars is forecast to a readjusted size of US$ 837640 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Biologics and Biosimilars market. Biologics and Biosimilars are expected to show stable growth in the futu......
  • Global Biosimilar Drug Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Biosimilar Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Biosimilar Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Biosimilar Drug market. Biosimilar Drug are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Biologics and Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 147
    According to our (Global Info Research) latest study, the global Biologics and Biosimilars market size was valued at USD 481830 million in 2023 and is forecast to a readjusted size of USD 842330 million by 2030 with a CAGR of 8.3% during review period. Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin......
  • Global Biosimilars Market Research Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 2680 Onwards        Pages: 167
    A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
  • Global Biosimilars Professional Survey Report 2023, Forecast to 2028
    Published: 27-Dec-2023        Price: US 3280 Onwards        Pages: 133
    A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......
  • Global Biosimilars Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Biosimilars market: According to our latest research, the global Biosimilars market looks promising in the next 5 years. As of 2022, the global Biosimilars market was estimated at USD 8203.97 million, and it's anticipated to reach USD 40650.01 million in 2028, with a CAGR of 30.57% during the forecast years. A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA?approved biologic product......
  • Global Biologics and Biosimilars Professional Survey Report 2023, Forecast to 2028
    Published: 24-Nov-2023        Price: US 3280 Onwards        Pages: 134
    Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
  • Global Biologics and Biosimilars Market Research Report 2023, Forecast to 2028
    Published: 24-Nov-2023        Price: US 2680 Onwards        Pages: 160
    Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......
  • Global Biosimilar Monoclonal Antibodies Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 103
    Market Overview of Global Biosimilar Monoclonal Antibodies market: According to our latest research, the global Biosimilar Monoclonal Antibodies market looks promising in the next 5 years. As of 2022, the global Biosimilar Monoclonal Antibodies market was estimated at USD 5156.19 million, and it's anticipated to reach USD 14274.14 million in 2028, with a CAGR of 18.5% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs